Video

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

Author(s):

Patricia M. LoRusso, DO

In Partnership With:

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

A trial, funded by both Stand Up 2 Cancer and the Melanoma Research Alliance investigated the use of next-generation sequencing technology to examine both the normal and cancer genome of patients with metastatic melanoma who have progressed on immunotherapy or can not use immunotherapeutic intervention.

Based on the results of the complex sequencing, treatment regimens are designed based on the individual molecular signatures of each patient’s tumor.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Justin M. Watts, MD
July 22nd 2024

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital
April 29th 2024

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

Sidi Chen, PhD
July 14th 2024

Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Vivek Subbiah, MD, chief, early-phase drug development, Sarah Cannon Research Institute
July 11th 2024

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

Neil D. Gross, MD, FACS
July 10th 2024

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC